Drug Profile
Research programme: viral infection therapeutics - Gemmus Pharma
Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Gemmus Pharma
- Class Eicosanoids
- Mechanism of Action Eicosanoid receptor agonists; G protein-coupled receptor agonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Viral infections
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Viral-infections in USA
- 06 Jan 2020 Early research development in is ongoing in the US (Gemmus pharma pipeline, January 2020)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (PO)